Microcardix is the next generation endovascular biopsy technique, especially suited for the heart. It is more flexible and less traumatic than conventional devices and is designed to be used with modern molecular analysis techniques.
Our Technology
Microcardix is an endovascular microcatheter-based device that designed for harvesting minimal tissue samples of the heart and organs near major vessels, such as the lungs, liver, and kidneys. In the heart, the device has a favorable safety profile compared to conventional devices, due to its small size and mechanism of action. Patent pending.
Microcardix
Team
Rikard Grankvist
CEO
MD, PhD.
Staffan Holmin
CMO
MD, Prof.
Magnus Settergren
Director of Clinical Affairs
MD, Assoc. Prof.
Mikael Sandell
CTO
MSc Eng.
Arvin Chireh
Head of Molecular Analysis
MD, PhD.
Stefan Jonsson
Technical Director
Prof.
Publications
1. Grankvist, R. et al. Myocardial micro-biopsy procedure for molecular characterization with increased precision and reduced trauma. Scientific Reports 10, 1–11 (2020).
2. Chireh, A. et al. Micro-biopsy for detection of gene expression changes in ischemic swine myocardium: A pilot study. PLoS One 16, e0250582 (2021).
3. Chireh, A. et al. Safety evaluation of high-risk myocardial micro-biopsy in a swine model. Heart Vessels (2021) doi:10.1007/s00380-021-01995-9.
About the company
Microcardix was founded in 2020 as a spin out from Karolinska Institutet. It is part of KI Innovations incubator DRIVE.
News
2023-12-15: Microcardix procuring CMO
Microcardix is currently in the process of procuring a contract manufacturing organization (CMO) to aid in the development and production of a clinically viable prototype of the Microcardix Micro-Biopsy heart biopsy device, as well as related services such as packaging, sterile preparation, biocompatibility and associated testing.
The Micro-Biopsy technique has been evaluated in pre-clinical trials using in-house manufacturing, but there is now a need for improved, scalable manufacturing of the device. Interested CMOs can contact our CEO.
2023-11-07: Microcardix to present at KI SciencePark Day
Microcardix has been invited to present our company and our novel biopsy technique, November 15th at KI Science Park Day, Biomedicum, Karolinska Institutet. The theme for this year's KI Science Park Day is "Unlocking Synergy", which is a great tagline for how Microcardix and our biopsy device came to be!
The Microcardix Micro-Biopsy technique can provide safer and easier access to all parts of the heart that are difficult or unsafe to reach with clinically available devices. By addressing the limitations of current biopsy methods, our method may have a significant impact on the management and understanding of heart disease.
2023-09-26: Microcardix participates in Nordic Innovation Fair, wins best pitch
Microcardix went to Copenhagen to participate in the Nordic Innovation Fair, a meeting between universities, start-ups and investors in the Life Science, Health & Medtech, and Greentech fields. CEO Rikard Grankvist pitched our heart biopsy device in the Medtech session and was awarded best pitch by the jury of investors.
2023-04-19: Microcardix awarded best pitch at Karolinska Institutet Innovations InvestorDay
Microcardix participated in InvestorDay, a meet-up between incubator companies at Karolinska Institutet Innovations, and investors and members of the health and life science industry. CEO Rikard Grankvist pitched to investors and was awarded the best pitch by audience vote.